ArticleTherapeutic advances in gastroenterology2012
Treatment of resectable gastric cancer.
Article in Therapeutic advances in gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis.Oncotarget · 2017Pooled it
- Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer.World journal of gastroenterology · 2014Pooled it
- The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.Medicine · 2016Trial
- A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer.Medical oncology (Northwood, London, England) · 2015Trial
- Design, synthesis, and evaluation of cyclic C7-bridged monocarbonyl curcumin analogs containing anJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities.Journal of gastrointestinal cancer · 2024Review
- Mutational separation and clinical outcomes ofWorld journal of gastrointestinal surgery · 2023Article
- Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma.Annals of surgical oncology · 2022Article
- CRISPR/Cas9 Genome-Editing Technology and Potential Clinical Application in Gastric Cancer.Genes · 2022Review
- Article
- The Discordance of Clinical and Pathologic Staging in Locally Advanced Gastric Adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Development and validation of an individual alternative splicing prognostic signature in gastric cancer.Aging · 2021Article
- Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.Journal of experimental & clinical cancer research : CR · 2020Article
- Observational
- A DNA methylation signature to improve survival prediction of gastric cancer.Clinical epigenetics · 2020Article
- High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Alantolactone induces gastric cancer BGC-823 cell apoptosis by regulating reactive oxygen species generation and the AKT signaling pathway.Oncology letters · 2019Article
- CD133 Expression as aAnticancer research · 2018Article
- Sijunzi decoction-treated rat serum induces apoptosis of side population cells in gastric carcinoma.Experimental and therapeutic medicine · 2018Article
- Survival benefits of gastrectomy in gastric cancer patients with stage IV: a population-based study.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stomach cancer is one of the most common cancers worldwide, despite its declining overall incidence. Although there are differences in incidence, etiology and pathological factors, most studies do not separately analyze cardia and noncardia gastric cancer. Surgery is the only potentially curative treatment for advanced, resectable gastric cancer, but locoregional relapse rate is high with a consequently poor prognosis. To improve survival, several preoperative and postoperative treatment strategies have been investigated. Whereas perioperative chemotherapy and postoperative chemoradiation (CRT) are considered standard therapy in the Western world, in Asia postoperative monochemotherapy with S-1 is often used. Several other therapeutic options, although generally not accepted as standard treatment, are postoperative combination chemotherapy, hyperthermic intraperitoneal chemotherapy and preoperative radiotherapy and CRT. Postoperative combination chemotherapy does show a statistically significant but clinically equivocal survival advantage in several meta-analyses. Hyperthermic intraperitoneal chemotherapy is mainly performed in Asia and is associated with a higher postoperative complication rate. Based on the currently available data, the use of postoperative radiotherapy alone and the use of intraoperative radiotherapy should not be advised in the treatment of resectable gastric cancer. Western randomized trials on gastric cancer are often hampered by slow or incomplete accrual. Reduction of toxicity for preoperative and especially postoperative treatment is essential for the ongoing improvement of gastric cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.